Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen

Akira Shimada, Yoshiyuki Takahashi, Hideki Muramatsu, Asahito Hama, Olfat Ismael, Atsushi Narita, Hiroshi Sakaguchi, Sayoko Doisaki, Nobuhiro Nishio, Makito Tanaka, Nao Yoshida, Kimikazu Matsumoto, Koji Kato, Nobuhiro Watanabe, Seiji Kojima

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Fanconi anemia (FA) is a disorder characterized by developmental anomalies, bone marrow failure and a predisposition to malignancy. It has recently been shown that hematopoietic stem cell transplantation using fludarabine (FLU)-based reduced-intensity conditioning is an efficient and quite safe therapeutic modality. We retrospectively analyzed the outcome of bone marrow transplantation (BMT) in eight patients with FA performed in two institutes between 2001 and 2011. There were seven females and one male with a median age at diagnosis = 4.5 years (range 2-12 years). The constitutional characteristics associated with FA, such as developmental anomalies, short stature and skin pigmentation, were absent in three of the patients. One patient showed myelodysplastic features at the time of BMT. All patients received BMT using FLU, cyclophosphamide (CY) and rabbit antithymocyte globulin (ATG) either from a related donor (n = 4) or an unrelated donor (n = 4). Acute graft-versushost disease (GVHD) of grade I developed in one patient, while chronic GVHD was not observed in any patient. All patients are alive and achieved hematopoietic recovery at a median follow-up of 72 months (range 4-117 months). BMT using FLU/low-dose CY/ATG -based regimens regardless to the donor is a beneficial therapeutic approach for FA patients.

Original languageEnglish
Pages (from-to)675-679
Number of pages5
JournalInternational Journal of Hematology
Volume95
Issue number6
DOIs
Publication statusPublished - Jun 2012
Externally publishedYes

Fingerprint

Fanconi Anemia
Homologous Transplantation
Bone Marrow Transplantation
Antilymphocyte Serum
Cyclophosphamide
Tissue Donors
Skin Pigmentation
Transplants
Unrelated Donors
fludarabine
Hematopoietic Stem Cell Transplantation
Bone Marrow
Rabbits

Keywords

  • Fanconi anemia
  • Fludarabine
  • Hematopoietic stem cell transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen. / Shimada, Akira; Takahashi, Yoshiyuki; Muramatsu, Hideki; Hama, Asahito; Ismael, Olfat; Narita, Atsushi; Sakaguchi, Hiroshi; Doisaki, Sayoko; Nishio, Nobuhiro; Tanaka, Makito; Yoshida, Nao; Matsumoto, Kimikazu; Kato, Koji; Watanabe, Nobuhiro; Kojima, Seiji.

In: International Journal of Hematology, Vol. 95, No. 6, 06.2012, p. 675-679.

Research output: Contribution to journalArticle

Shimada, A, Takahashi, Y, Muramatsu, H, Hama, A, Ismael, O, Narita, A, Sakaguchi, H, Doisaki, S, Nishio, N, Tanaka, M, Yoshida, N, Matsumoto, K, Kato, K, Watanabe, N & Kojima, S 2012, 'Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen', International Journal of Hematology, vol. 95, no. 6, pp. 675-679. https://doi.org/10.1007/s12185-012-1079-9
Shimada, Akira ; Takahashi, Yoshiyuki ; Muramatsu, Hideki ; Hama, Asahito ; Ismael, Olfat ; Narita, Atsushi ; Sakaguchi, Hiroshi ; Doisaki, Sayoko ; Nishio, Nobuhiro ; Tanaka, Makito ; Yoshida, Nao ; Matsumoto, Kimikazu ; Kato, Koji ; Watanabe, Nobuhiro ; Kojima, Seiji. / Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen. In: International Journal of Hematology. 2012 ; Vol. 95, No. 6. pp. 675-679.
@article{f352a41b4bca4b4298f67df328729675,
title = "Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen",
abstract = "Fanconi anemia (FA) is a disorder characterized by developmental anomalies, bone marrow failure and a predisposition to malignancy. It has recently been shown that hematopoietic stem cell transplantation using fludarabine (FLU)-based reduced-intensity conditioning is an efficient and quite safe therapeutic modality. We retrospectively analyzed the outcome of bone marrow transplantation (BMT) in eight patients with FA performed in two institutes between 2001 and 2011. There were seven females and one male with a median age at diagnosis = 4.5 years (range 2-12 years). The constitutional characteristics associated with FA, such as developmental anomalies, short stature and skin pigmentation, were absent in three of the patients. One patient showed myelodysplastic features at the time of BMT. All patients received BMT using FLU, cyclophosphamide (CY) and rabbit antithymocyte globulin (ATG) either from a related donor (n = 4) or an unrelated donor (n = 4). Acute graft-versushost disease (GVHD) of grade I developed in one patient, while chronic GVHD was not observed in any patient. All patients are alive and achieved hematopoietic recovery at a median follow-up of 72 months (range 4-117 months). BMT using FLU/low-dose CY/ATG -based regimens regardless to the donor is a beneficial therapeutic approach for FA patients.",
keywords = "Fanconi anemia, Fludarabine, Hematopoietic stem cell transplantation",
author = "Akira Shimada and Yoshiyuki Takahashi and Hideki Muramatsu and Asahito Hama and Olfat Ismael and Atsushi Narita and Hiroshi Sakaguchi and Sayoko Doisaki and Nobuhiro Nishio and Makito Tanaka and Nao Yoshida and Kimikazu Matsumoto and Koji Kato and Nobuhiro Watanabe and Seiji Kojima",
year = "2012",
month = "6",
doi = "10.1007/s12185-012-1079-9",
language = "English",
volume = "95",
pages = "675--679",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen

AU - Shimada, Akira

AU - Takahashi, Yoshiyuki

AU - Muramatsu, Hideki

AU - Hama, Asahito

AU - Ismael, Olfat

AU - Narita, Atsushi

AU - Sakaguchi, Hiroshi

AU - Doisaki, Sayoko

AU - Nishio, Nobuhiro

AU - Tanaka, Makito

AU - Yoshida, Nao

AU - Matsumoto, Kimikazu

AU - Kato, Koji

AU - Watanabe, Nobuhiro

AU - Kojima, Seiji

PY - 2012/6

Y1 - 2012/6

N2 - Fanconi anemia (FA) is a disorder characterized by developmental anomalies, bone marrow failure and a predisposition to malignancy. It has recently been shown that hematopoietic stem cell transplantation using fludarabine (FLU)-based reduced-intensity conditioning is an efficient and quite safe therapeutic modality. We retrospectively analyzed the outcome of bone marrow transplantation (BMT) in eight patients with FA performed in two institutes between 2001 and 2011. There were seven females and one male with a median age at diagnosis = 4.5 years (range 2-12 years). The constitutional characteristics associated with FA, such as developmental anomalies, short stature and skin pigmentation, were absent in three of the patients. One patient showed myelodysplastic features at the time of BMT. All patients received BMT using FLU, cyclophosphamide (CY) and rabbit antithymocyte globulin (ATG) either from a related donor (n = 4) or an unrelated donor (n = 4). Acute graft-versushost disease (GVHD) of grade I developed in one patient, while chronic GVHD was not observed in any patient. All patients are alive and achieved hematopoietic recovery at a median follow-up of 72 months (range 4-117 months). BMT using FLU/low-dose CY/ATG -based regimens regardless to the donor is a beneficial therapeutic approach for FA patients.

AB - Fanconi anemia (FA) is a disorder characterized by developmental anomalies, bone marrow failure and a predisposition to malignancy. It has recently been shown that hematopoietic stem cell transplantation using fludarabine (FLU)-based reduced-intensity conditioning is an efficient and quite safe therapeutic modality. We retrospectively analyzed the outcome of bone marrow transplantation (BMT) in eight patients with FA performed in two institutes between 2001 and 2011. There were seven females and one male with a median age at diagnosis = 4.5 years (range 2-12 years). The constitutional characteristics associated with FA, such as developmental anomalies, short stature and skin pigmentation, were absent in three of the patients. One patient showed myelodysplastic features at the time of BMT. All patients received BMT using FLU, cyclophosphamide (CY) and rabbit antithymocyte globulin (ATG) either from a related donor (n = 4) or an unrelated donor (n = 4). Acute graft-versushost disease (GVHD) of grade I developed in one patient, while chronic GVHD was not observed in any patient. All patients are alive and achieved hematopoietic recovery at a median follow-up of 72 months (range 4-117 months). BMT using FLU/low-dose CY/ATG -based regimens regardless to the donor is a beneficial therapeutic approach for FA patients.

KW - Fanconi anemia

KW - Fludarabine

KW - Hematopoietic stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84864984364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864984364&partnerID=8YFLogxK

U2 - 10.1007/s12185-012-1079-9

DO - 10.1007/s12185-012-1079-9

M3 - Article

C2 - 22527854

AN - SCOPUS:84864984364

VL - 95

SP - 675

EP - 679

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 6

ER -